Niemann-Pick Type C (NPC) disease is a genetic, neurodegenerative disorder which causes progressive deterioration of the nervous system.
It usually affects children by interfering with their ability to metabolize cholesterol. Adult onset may also occur. Large amounts of cholesterol accumulate within the liver, spleen, and brain. This metabolic disorder leads to a series of neurological problems that are ultimately fatal…until a treatment is found.
In 1997 medical researchers funded by the Parseghian Foundation identified the location of a gene called NPC1 that is abnormal in patients with Niemann-Pick Type C disease. The NPC1 gene is on chromosome 18 and is normally present in two copies in each cell of the body. However, alterations or mutations in this gene cause about 95 percent of cases of NPC disease. In a second smaller group of patients with NPC, alternations in NPC1 do not cause the disease. Researchers suspect a second gene, called NPC2, may be responsible. Niemann-Pick Type C disease is known as an autosomal recessive inherited condition. This means that each parent of an affected child has one functional NPC1 gene, plus one non-functional NPC1 (or more rarely, NPC2) gene. These parents are called carriers, or heterozygotes, and exhibit no signs or symptoms of the disease. Affected children inherit two non-functional NP-C genes from their parents. In each pregnancy of a carrier couple, there is a one in four (25 percent) chance that they will both pass their non-functional NPC genes to a child who would then be affected. There is a one in two (50 percent) chance that only one of them would pass a non-functional gene. The child would then be a carrier like the parents. There is a 25 percent chance that both functional genes would be passed and the child would be neither a carrier nor affected with the disease.
Niemann-Pick Type C Caregiver Preference Survey on Benefit Risk for Potential TreatmentsOctober 28, 2020
Positive results reported from IntraBio’s multinational clinical trial with IB1001 for treatment of Niemann-Pick disease Type COctober 6, 2020
Conversation with Dr. Elizabeth Berry-Kravis & Mallinckrodt in regards to Adrabetadex Transition to EAPJuly 22, 2020
See All Research Stories